Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation

Małgorzata Pawłowska; Robert Flisiak; Lidia Gil; Andrzej Horban; Iwona Hus; Jerzy Jaroszewicz; Ewa Lech-Marańda; Jan Styczyński

doi:10.5114/ceh.2019.87631

eISSN: 2449-8238
ISSN: 2392-1099

Clinical and Experimental Hepatology

Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2019
vol. 5

Send email

Copy url:

abstract:

Review paper

Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation

Małgorzata Pawłowska

¹

,

Robert Flisiak

²

,

Lidia Gil

³

,

Andrzej Horban

⁴

,

Iwona Hus

^{5, 6}

,

Jerzy Jaroszewicz

⁷

,

Ewa Lech-Marańda

⁵

,

Jan Styczyński

⁸

Department of Infectious Diseases and Hepatology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland
Department of Infectious Diseases and Hepatology, Medical University of Białystok, Poland
Department of Haematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poland
Provincial Hospital of Infectious Diseases and Medical University in Warsaw, Poland
Department of Haematology, Institute of Haematology and Transfusion Medicine in Warsaw, Poland
Department of Clinical Transplantology, Medical University of Lublin, Poland
Department and Clinical Unit of Infectious Diseases and Hepatology, Medical University of Silesia in Katowice, Poland
Department of Paediatrics, Haematology and Oncology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland

Clin Exp HEPATOL 2019; 5, 3:195–202

DOI: https://doi.org/10.5114/ceh.2019.87631

Online publish date: 2019/09/05

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Pawłowska M, Flisiak R, Gil L, et al. Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation. Clinical and Experimental Hepatology. 2019;5(3):195-202. doi:10.5114/ceh.2019.87631.

APA

Pawłowska, M., Flisiak, R., Gil, L., Horban, A., Hus, I.,  & Jaroszewicz, J. et al. (2019). Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation. Clinical and Experimental Hepatology, 5(3), 195-202. https://doi.org/10.5114/ceh.2019.87631

Chicago

Pawłowska, Małgorzata, Robert Flisiak, Lidia Gil, Andrzej Horban, Iwona Hus, Jerzy Jaroszewicz,  and Ewa Lech-Marańda et al. 2019. "Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation". Clinical and Experimental Hepatology 5 (3): 195-202. doi:10.5114/ceh.2019.87631.

Harvard

Pawłowska, M., Flisiak, R., Gil, L., Horban, A., Hus, I., Jaroszewicz, J., Lech-Marańda, E.,  and Styczyński, J. (2019). Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation. Clinical and Experimental Hepatology, 5(3), pp.195-202. https://doi.org/10.5114/ceh.2019.87631

MLA

Pawłowska, Małgorzata et al. "Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation." Clinical and Experimental Hepatology, vol. 5, no. 3, 2019, pp. 195-202. doi:10.5114/ceh.2019.87631.

Vancouver

Pawłowska M, Flisiak R, Gil L, Horban A, Hus I, Jaroszewicz J et al. Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation. Clinical and Experimental Hepatology. 2019;5(3):195-202. doi:10.5114/ceh.2019.87631.

PlumX metrics:

Hepatitis B virus (HBV) is one of the main causes of chronic liver diseases and hepatocellular carcinoma. After infection the majority of HBV-infected patients achieve immune control leading to HBV-DNA stabilization at a low level. The risk of HBV reactivation rises significantly when HBV-infected patients receive immunosuppressive treatments. Presented recommendations provide guidelines for management of patients scheduled or undergoing therapies, which through their immunomodulatory activity contribute to the impairment of antiviral immunity, including chemotherapy, immunosuppressive treatment or biological therapy.

keywords:

Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation

Małgorzata Pawłowska 1 , Robert Flisiak 2 , Lidia Gil 3 , Andrzej Horban 4 , Iwona Hus 5, 6 , Jerzy Jaroszewicz 7 , Ewa Lech-Marańda 5 , Jan Styczyński 8

HBV, prevention, reactivation

Małgorzata Pawłowska

¹

,

Robert Flisiak

²

,

Lidia Gil

³

,

Andrzej Horban

⁴

,

Iwona Hus

^{5, 6}

,

Jerzy Jaroszewicz

⁷

,

Ewa Lech-Marańda

⁵

,

Jan Styczyński

⁸